# Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI or FOLFOX in First Line (VALIDATE)

> **NCT03043950** · — · COMPLETED · sponsor: **iOMEDICO AG** · enrollment: 647 (actual)

## Conditions studied

- Metastatic Colorectal Cancer
- RAS Wild-type

## Interventions

- **DRUG:** Panitumumab

## Key facts

- **NCT ID:** NCT03043950
- **Lead sponsor:** iOMEDICO AG
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-25
- **Primary completion:** 2024-01-17
- **Final completion:** 2024-01-17
- **Target enrollment:** 647 (ACTUAL)
- **Last updated:** 2024-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03043950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03043950, "Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI or FOLFOX in First Line (VALIDATE)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03043950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*